Use of anti-MCAM antibodies for the treatment or prevention of giant cell arteritis, polymyalgia rheumatica or Takayasu arteritis

摘要

The present invention relates to anti-MCAM antibodies that inhibit the ability of human MCAM to bind laminin alpha-4 chain, and for use in the treatment or prevention of giant cell arteritis, rheumatoid polymyalgia (PMR) or Takayasu arteritis. The present invention provides pharmaceutical compositions and pharmaceutical formulations incorporating it, methods for generating such antibodies, and their use in the manufacture of a medicament for the treatment of neuroinflammatory diseases, autoimmune diseases, or cancer. [Selection] Figure 1